Wuhan General Group (China), Inc. (WUHN)

Market Cap	5.52K
Revenue (ttm)	80.38M
Net Income (ttm)	-11.32M
Shares Out	55.15M
EPS (ttm)	-0.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,286
Average Volume	11,669
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0002
Beta	-45.48
RSI	41.95
Earnings Date	n/a

About WUHN

Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Jeffrey Robinson
• Employees: 700
• Stock Exchange: OTCMKTS
• Ticker Symbol: WUHN

Financial Performance

In 2012, WUHN's revenue was $80.38 million, a decrease of -36.96% compared to the previous year's $127.50 million. Losses were -$11.32 million, 146.8% more than in 2011.